New York State Common Retirement Fund Buys 2,078 Shares of Zoetis Inc. $ZTS

New York State Common Retirement Fund grew its position in Zoetis Inc. (NYSE:ZTS) by 0.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 563,929 shares of the company’s stock after purchasing an additional 2,078 shares during the period. New York State Common Retirement Fund owned about 0.13% of Zoetis worth $87,945,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Nova Wealth Management Inc. acquired a new position in Zoetis in the first quarter valued at about $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank acquired a new position in shares of Zoetis in the 1st quarter worth approximately $29,000. REAP Financial Group LLC grew its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC increased its holdings in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Stifel Nicolaus reduced their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. KeyCorp started coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Argus restated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Price Performance

Shares of ZTS stock opened at $128.18 on Friday. The firm has a market cap of $56.49 billion, a price-to-earnings ratio of 22.06, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a 50-day moving average price of $135.77 and a 200 day moving average price of $149.01.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the prior year, the company posted $1.58 EPS. The company’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.